Novel immunotherapies in multiple myeloma: chances and challenges
In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 1, 2021
|
| In: |
Haematologica
Year: 2021, Volume: 106, Issue: 10, Pages: 2555-2565 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2020.266858 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.2020.266858 Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/haematol.2020.266858 
|
| Author Notes: | Leo Rasche, Ralph Wäsch, Markus Munder, Hartmut Goldschmidt and Marc S. Raab |
| Summary: | In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials. |
|---|---|
| Item Description: | Gesehen am 04.02.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2020.266858 |